In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sage Therapeutics nets $561mm in FOPO

Executive Summary

Sage Therapeutics Inc. (focused on selective allosteric GABAA modulation) netted $561.3mm through the public offering of 3.8mm shares (including the overallotment) at $150. Sage will put the proceeds toward the US commercial launch of Zulresso (SAGE547; brexanolone) for postpartum depression, if approved (an NDA was filed in 2018 with an extended PDUFA date of March 19, 2019); ongoing development of and initial pre-commercial activities for SAGE217 in major depressive disorder (Phase III), bipolar depression (Phase II), and insomnia (Phase I); and advancement of Phase I candidates SAGE324 (essential tremor and epileptiform disorders) and SAGE718 (cognition-related disorders, including Huntington’s disease).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies